Lamotrigine Tablet
Product Images NDC 42291-367

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 42291-367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 4229136610 Lamotrigine 25mg 2018

Lamotrigine Tablets USP 25 mg oral tablets in a bottle containing 1000 tablets. The packaging features the labeler AvKARE, including NDC 42291-366-10 and a caution to verify the product dispensed. Additional instructions and a barcode are visible on the label.*

FDA Label Image

Label 4229136710 Lamotrigine 2019 100mg 1000ct

Lamotrigine Tablets USP 100 mg oral tablets label by AvKARE. The label indicates a quantity of 1000 tablets, with caution to verify the dispensed product. It includes patient medication use instructions, storage conditions, and manufacturer information from AvKARE, Memphis, TN.*

FDA Label Image

Label 4229136860 Lamotrigine 2018 150mg

Label for Lamotrigine Tablets, USP 150 mg oral tablets by AvKARE. The label includes the NDC 42291-368-60, directions for pharmacists to dispense the Medication Guide with each patient, storage instructions, warnings, caution to verify the product dispensed, and states the package contains 60 tablets for prescription use only.*

FDA Label Image

Label 4229136950 Lamotrigine 2018 200mg

Label for Lamotrigine Tablets, USP 200 mg by AvKARE. The label indicates the product contains 500 tablets for oral use, with a caution to verify the product dispensed. It lists storage instructions and dispensing information, and includes the NDC 42291-369-50 along with barcode and manufacturer details.*

FDA Label Image

Figure1

A survival analysis chart showing failure probability (%) over time in weeks comparing Lamotrigine and Placebo groups. The plot includes censored data points for both groups and illustrates the difference in failure probability trends between Lamotrigine and Placebo treatments over approximately 90 weeks.*

FDA Label Image

Figure2

A line graph showing failure probability (%) over weeks comparing Lamotrigine and Placebo groups. The x-axis represents weeks (0 to 80), and the y-axis represents failure probability (0% to 100%). The graph features two curves, one labeled Lamotrigine with a lower failure probability trend over time, and another labeled Placebo with a higher failure probability. Censored data points are indicated by plus signs on the curves.*

FDA Label Image

Chemical Structure (Lamotriginestructrue)

Chemical structure of lamotrigine, showing the molecular framework including chlorine atoms and amino groups connected to a triazine ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.